Jonah Feldman

Topical ruxolitinib cream resulted in benefit to patients with cutaneous chronic graft-vs-host based on results of a trial that were presented at the 2022 Tandem Meeting.

Investigators uncovered potential mechanisms of resistance to CD19-directed CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia.

The CAR T-cell product BNT211 when used with or without a CAR T cell–amplifying RNA vaccine produced considerable responses and safety in patients with CLDN6-positive advanced solid tumors.

Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.

Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.

Acalabrutinib produced positive quality-adjusted survival benefits over other treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Standard of care treatment was superior to the combination of ibrutinib plus venetoclax in terms of decreasing minimal residual disease for previously untreated patients with chronic lymphocytic leukemia.

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.